BofA Securities Downgrades PTC Therapeutics (PTCT) to Neutral
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $71.70 -0.38%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $62.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PTC Therapeutics (PTCT) PT Raised to $122 at Barclays
- UBS Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
- JPMorgan Downgrades KinderCare Learning Companies (KLC) to Underweight
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
